We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic (MDT): Will Currency Woes Hurt Q4 As Well?
Read MoreHide Full Article
On May 26, 2016, we issued an updated research report on Medtronic plc (MDT - Free Report) . The company, which is slated to report its fourth-quarter and fiscal 2016 earnings on May 31, had missed the Zacks Consensus Estimate for revenues in the third quarter while earnings met the mark.
Unfavorable currency movements had been a major dampener during the third quarter, as in the case of other important MedTech players too. With the trend expected to linger, the company’s revenues may be hit by fluctuations in foreign exchange rates, going forward. Considering this impact, for the fourth quarter of fiscal 2016, Medtronic expects currency headwinds to the tune of approximately $180−$220 million (based on current exchange rates) on revenues.
However, the consolidated company demonstrated strong segmental performances in the third quarter, reflecting successful integration and achievement of synergy targets. All four major business groups contributed to solid top-line growth in the last reported quarter, demonstrating sustainability across groups and regions.
According to management, the Covidien integration is on track and is meaningfully accelerating all three fundamental growth strategies of Medtronic – therapy innovation, globalization and economic value.
The combined company should generate significant free cash flow, a substantial percentage of which will be deployed with much greater flexibility. This cash flow will ensure better investment in U.S. healthcare technologies as well as enhanced shareholder returns.
Medtronic is resorting to all possible means to boost growth. This includes penetration in emerging markets, expansion of its portfolio and restructuring of initiatives. These should benefit the company over the long term. We are also encouraged by Medtronic’s recent foray into the rapid growing transcatheter mitral valve replacement (TMVR) market through its recently completed $458 million acquisition of California-based medical device start-up firm – Twelve, Inc.
However, on the flip side, we note that the company is currently entangled in multiple legal issues which are weighing on the bottom line. Moreover, a soft economy and tough competition headwinds keep us on the sidelines.
At the moment, Medtronic retains a Zacks Rank #3 (Hold).
Key Picks in the Sector
Some medical product stocks worth a look are Boston Scientific Corporation (BSX - Free Report) , ICU Medical, Inc. (ICUI - Free Report) and LeMaitre Vascular, Inc. (LMAT - Free Report) . All three stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Medtronic (MDT): Will Currency Woes Hurt Q4 As Well?
On May 26, 2016, we issued an updated research report on Medtronic plc (MDT - Free Report) . The company, which is slated to report its fourth-quarter and fiscal 2016 earnings on May 31, had missed the Zacks Consensus Estimate for revenues in the third quarter while earnings met the mark.
Unfavorable currency movements had been a major dampener during the third quarter, as in the case of other important MedTech players too. With the trend expected to linger, the company’s revenues may be hit by fluctuations in foreign exchange rates, going forward. Considering this impact, for the fourth quarter of fiscal 2016, Medtronic expects currency headwinds to the tune of approximately $180−$220 million (based on current exchange rates) on revenues.
However, the consolidated company demonstrated strong segmental performances in the third quarter, reflecting successful integration and achievement of synergy targets. All four major business groups contributed to solid top-line growth in the last reported quarter, demonstrating sustainability across groups and regions.
According to management, the Covidien integration is on track and is meaningfully accelerating all three fundamental growth strategies of Medtronic – therapy innovation, globalization and economic value.
The combined company should generate significant free cash flow, a substantial percentage of which will be deployed with much greater flexibility. This cash flow will ensure better investment in U.S. healthcare technologies as well as enhanced shareholder returns.
Medtronic is resorting to all possible means to boost growth. This includes penetration in emerging markets, expansion of its portfolio and restructuring of initiatives. These should benefit the company over the long term. We are also encouraged by Medtronic’s recent foray into the rapid growing transcatheter mitral valve replacement (TMVR) market through its recently completed $458 million acquisition of California-based medical device start-up firm – Twelve, Inc.
However, on the flip side, we note that the company is currently entangled in multiple legal issues which are weighing on the bottom line. Moreover, a soft economy and tough competition headwinds keep us on the sidelines.
At the moment, Medtronic retains a Zacks Rank #3 (Hold).
Key Picks in the Sector
Some medical product stocks worth a look are Boston Scientific Corporation (BSX - Free Report) , ICU Medical, Inc. (ICUI - Free Report) and LeMaitre Vascular, Inc. (LMAT - Free Report) . All three stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>